Vaccines against Group B Coxsackieviruses and Their Importance

The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4...

Descripción completa

Detalles Bibliográficos
Autores principales: Mone, Kiruthiga, Lasrado, Ninaad, Sur, Meghna, Reddy, Jay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961666/
https://www.ncbi.nlm.nih.gov/pubmed/36851152
http://dx.doi.org/10.3390/vaccines11020274
_version_ 1784895811194191872
author Mone, Kiruthiga
Lasrado, Ninaad
Sur, Meghna
Reddy, Jay
author_facet Mone, Kiruthiga
Lasrado, Ninaad
Sur, Meghna
Reddy, Jay
author_sort Mone, Kiruthiga
collection PubMed
description The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D.
format Online
Article
Text
id pubmed-9961666
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99616662023-02-26 Vaccines against Group B Coxsackieviruses and Their Importance Mone, Kiruthiga Lasrado, Ninaad Sur, Meghna Reddy, Jay Vaccines (Basel) Review The group B coxsackieviruses (CVBs) exist in six serotypes (CVB1 to CVB6). Disease associations have been reported for most serotypes, and multiple serotypes can cause similar diseases. For example, CVB1, CVB3, and CVB5 are generally implicated in the causation of myocarditis, whereas CVB1 and CVB4 could accelerate the development of type 1 diabetes (T1D). Yet, no vaccines against these viruses are currently available. In this review, we have analyzed the attributes of experimentally tested vaccines and discussed their merits and demerits or limitations, as well as their impact in preventing infections, most importantly myocarditis and T1D. MDPI 2023-01-27 /pmc/articles/PMC9961666/ /pubmed/36851152 http://dx.doi.org/10.3390/vaccines11020274 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mone, Kiruthiga
Lasrado, Ninaad
Sur, Meghna
Reddy, Jay
Vaccines against Group B Coxsackieviruses and Their Importance
title Vaccines against Group B Coxsackieviruses and Their Importance
title_full Vaccines against Group B Coxsackieviruses and Their Importance
title_fullStr Vaccines against Group B Coxsackieviruses and Their Importance
title_full_unstemmed Vaccines against Group B Coxsackieviruses and Their Importance
title_short Vaccines against Group B Coxsackieviruses and Their Importance
title_sort vaccines against group b coxsackieviruses and their importance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961666/
https://www.ncbi.nlm.nih.gov/pubmed/36851152
http://dx.doi.org/10.3390/vaccines11020274
work_keys_str_mv AT monekiruthiga vaccinesagainstgroupbcoxsackievirusesandtheirimportance
AT lasradoninaad vaccinesagainstgroupbcoxsackievirusesandtheirimportance
AT surmeghna vaccinesagainstgroupbcoxsackievirusesandtheirimportance
AT reddyjay vaccinesagainstgroupbcoxsackievirusesandtheirimportance

Ejemplares similares